Navigation Links
Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce fourth quarter and year ended December 31, 2010 financial results on Thursday, March 10, 2011 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 788-0543 (domestic) or (857) 350-1681 (international), participant code 73770341. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com  and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response Letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
4. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
5. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
6. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
7. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
10. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
11. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance (CEA) ... series designed to educate children about the most common neurological ... Medikidz Explain Epilepsy comic series tells a fictional story ... middle school while living with epilepsy. "Despite ... is still so much misinformation and lack of awareness out ...
(Date:8/21/2014)... Kan. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Trust Alliance (HITRUST) under its Common Security Framework ... Enterprise Security and Privacy Manager, "We appreciate this ... level of commitment that this certification signifies. Our ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s ...
(Date:8/21/2014)... , Aug. 21, 2014  ACI Clinical ... for independent Data Monitoring Committees. Using ... 30 percent over industry standard costs and receive ... industry leader in committee services. Leveraging ... recruitment and contracting, charter development, statistical programming and ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3ScriptPro Achieves HITRUST Certification 2ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... statement was issued today by the law firm of Barroway ... hereby given that a class action lawsuit was filed in ... California on behalf of purchasers of the securities of SciClone ... "Company"), who purchased or otherwise acquired SciClone,s securities between May ...
... NVAX ) President and CEO Dr. Rahul Singhvi today ... Secretary Kathleen Sebelius and other public health officials announcing a ... vaccines to prevent the spread of infectious diseases and issued ... initiatives: Define and strengthen FDA regulatory processes ...
Cached Medicine Technology:Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 2Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP 3NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:8/22/2014)... August 22, 2014 Millennium Treatment ... in Lantana, FL, recently launched a new website. ... for information can now find Millennium Treatment Group ... just went live at the beginning of July. ... facility can be found on the website. There’s ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Beat ... how they can use natural methods to completely cure ... caught the attention of Shane Michaels, prompting an investigative ... that affects the skin, it can still be extremely ... reports Michaels. “The intense itching and pain that it ...
(Date:8/22/2014)... protein 11 (BIM) deletion in advanced non-small cell ... free survival (PFS) in epidermal growth factor receptor ... Asian patients. Also, BIM deletion independently predicts overall ... BIM protein can activate the programmed cell death ... BIM deletion has been detected in 12.8% of ...
(Date:8/22/2014)... factor receptor (EGFR) mutations found in the circulating free ... cell lung cancer (NSCLC) patients correlates well with the ... tyrosine kinase inhibitor (TKI) therapy is approved for EGFR ... standard for determining mutation status is with DNA derived ... not available. A more abundant and less invasive source ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3
... SAN JOSE, Calif., Sept. 2 MAQUET Cardiovascular ... complaint filed by Terumo,Cardiovascular Systems Corp. (Terumo CSC) ... District of California. The complaint alleges that,MAQUET,s VASOVIEW ... In April 2008, MAQUET filed patent infringement ...
... SANTA YNEZ VALLEY, Calif., Sept. 2 Platinum Performance,client McLain ... Summer Olympics in Beijing, China, on August 19, as "probably ... sport.", Winning the first ever jump-off in Olympic Games ... the Team Show Jumping title at the Hong Kong,Olympic Equestrian ...
... Sept. 2 MBF Healthcare,Acquisition Corp. (Amex: ... purpose,acquisition company, announced today the amendment of ... of Critical Homecare Solutions,Holdings, Inc. ("CHS"), based ... February 6, 2008 (the "Stock Purchase Agreement"). ...
... 2 Herley Industries,Inc. (Nasdaq: HRLY ), a ... solutions for the defense, aerospace and medical,industries worldwide, announced ... Jefferies & Company, Inc., as its financial,advisor to assist ... Myron Levy, Chairman and CEO, said, "We are pleased ...
... Help Payers and Providers Contain Costs and ... Improve Patient Outcomes Together, ... of Innovent Oncology, a service division that offers a first-time,opportunity ... designed specifically for the complexity of cancer,care. With a unique ...
... showed benefits even a year after routine was stopped, ... -- Exercise may help treat memory problems in adults, ... focused on 138 people age 50 and older at ... activity program led to modest improvements in cognitive function ...
Cached Medicine News:Health News:MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems 2Health News:Platinum Performance Clients Take Home Medals for the USA 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives 2Health News:US Oncology Launches New Services Division: Innovent Oncology 2Health News:US Oncology Launches New Services Division: Innovent Oncology 3Health News:US Oncology Launches New Services Division: Innovent Oncology 4Health News:Exercise May Help Prevent Age-Related Memory Loss 2
... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... forceps are extremely delicate and if repairs ... they can easily be damaged beyond repair ... endoscopes. , On the other hand, with ... can have a virtually indefinite lifespan. The ...
Medicine Products: